Efficacy and safety analysis of TACE combined with molecular targeted therapy and camrelizumab in the treatment of unresectable recurrent hepatocellular carcinoma
10.3760/cma.j.cn113884-20250325-00101
- VernacularTitle:TACE联合分子靶向治疗及卡瑞利珠单抗治疗不可切除复发性肝细胞癌的疗效和安全性分析
- Author:
Baizhu XIONG
1
;
Changlong HOU
1
;
Zhengfeng ZHANG
1
;
Xianhai ZHU
1
;
Yipeng FEI
1
;
Tao XIE
1
;
Changgao SHI
1
Author Information
1. 中国科学技术大学附属第一医院（安徽省立医院）介入科，合肥 230031
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Recurrence;
Prognosis;
Chemoembolization;
Immunotherapy
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(9):641-646
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy, safety, and prognostic factors of transarterial chemoembolization (TACE) combined with molecular targeted therapy (MTT) and camrelizumab in patients with unresectable recurrent hepatocellular carcinoma (urHCC).Methods:Clinical data of 83 patients with urHCC treated at the First Affiliated Hospital of the University of Science and Technology of China between October 2018 and October 2023 were retrospectively analyzed, including 75 males and 8 females, aged (55.2±10.7) years. Among them, 43 patients received TACE combined with MTT and camrelizumab (observation group), while 40 received TACE combined with MTT alone (control group). Kaplan-Meier curves were plotted to compare overall survival (OS) and progression-free survival (PFS) between the groups. Treatment response was assessed according to the mRECIST criteria, and objective response rate (ORR) and disease control rate (DCR) were compared. Adverse events (AEs) were monitored in both groups.Results:The observation group demonstrated longer median OS (31.8 vs 19.9 months, χ2=11.26, P=0.001) and median PFS (14.5 vs 7.4, months, χ2=4.08, P=0.043) compared to the control group. The ORR and DCR in the observation group were 51.2% (22/43) and 90.1% (39/43), respectively, both higher than those in the control group [25.0% (10/40) and 70.0% (28/40), respectively]. The differences were statistically significant ( χ2=5.99, 5.71; P=0.023, 0.025; respectively). Multivariate Cox analysis showed that different treatment regimens were influencing factors for post-treatment survival in patients with urHCC (control group vs treatment group: HR=2.633, 95% CI: 1.483- 4.677, P<0.001), as well as for PFS (control group vs treatment group: HR=1.781, 95% CI: 1.116-2.842, P=0.015). No treatment-related deaths or unexpected AEs occurred in either group. The most common systemic therapy-related AE was hand-foot syndrome, observed in 15 patients (34.9%, 15/43) in the observation group and 9 (22.5%, 9/40) in the control group ( χ2=1.55, P=0.236). Conclusions:Compared to TACE combined with MTT alone, TACE combined with MTT and camrelizumab demonstrates superior efficacy and acceptable safety in treating unresectable recurrent HCC.
